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Abstract
Background: Osteoclasts (OCs) are involved in rheumatoid arthritis and in several pathologies associated with
bone loss. Recent results support the concept that some medicinal plants and derived natural products are of
great interest for developing therapeutic strategies against bone disorders, including rheumatoid arthritis and
osteoporosis. In this study we determined whether extracts of Emblica officinalis fruits display activity of possible
interest for the treatment of rheumatoid arthritis and osteoporosis by activating programmed cell death of human
primary osteoclasts.
Methods: The effects of extracts from Emblica officinalis on differentiation and survival of human primary OCs
cultures obtained from peripheral blood were determined by tartrate-acid resistant acid phosphatase (TRAP)-
positivity and colorimetric MTT assay. The effects of Emblica officinalis extracts on induction of OCs apoptosis
were studied using TUNEL and immunocytochemical analysis of FAS receptor expression. Finally, in vitro effects
of Emblica officinalis extracts on NF-kB transcription factor activity were determined by gel shift experiments.
Results: Extracts of Emblica officinalis were able to induce programmed cell death of mature OCs, without
altering, at the concentrations employed in our study, the process of osteoclastogenesis. Emblica officinalis
increased the expression levels of Fas, a critical member of the apoptotic pathway. Gel shift experiments
demonstrated that Emblica officinalis extracts act by interfering with NF-kB activity, a transcription factor involved
in osteoclast biology. The data obtained demonstrate that Emblica officinalis extracts selectively compete with the
binding of transcription factor NF-kB to its specific target DNA sequences. This effect might explain the observed
effects of Emblica officinalis on the expression levels of interleukin-6, a NF-kB specific target gene.
Conclusion: Induction of apoptosis of osteoclasts could be an important strategy both in interfering with
rheumatoid arthritis complications of the bone skeleton leading to joint destruction, and preventing and reducing
osteoporosis. Accordingly, we suggest the application of Emblica officinalis extracts as an alternative tool for
therapy applied to bone diseases.
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Osteoclasts (OCs) are multinucleated cells of hematopoi-
etic origin and are the primary bone resorbing cells [1-4].
There is increasing evidence that OCs play a crucial role in
bone loss in rheumatoid arthritis [5-9], as recently
reported by Ochi et al. [5] and reviewed by several
authors, including Schett [6], Haynes [7], Tremoulet and
Albani [8], Boyce et al. [9], Sato and Takayanagi [10] and
Teitelbaum [11]. Abundant osteoclasts are found within
the synovial tissue at sites adjacent to bone, creating
resorption pits and local bone destruction followed by
degradation of the bone matrix and calcium solubiliza-
tion [6]. The basis of this behavior is that the synovial tis-
sue of inflamed joints harbor high concentrations of
monocytes/macrophages, which are osteoclast precursors,
as well as cells that provide the specific molecular signals
that drive osteoclast formation [6]. For instance, human
rheumatoid synovial lymphocytes and fibroblasts pro-
mote osteoclastogenic activity by activating the receptor
activator of NF-kB ligand (RANKL). The cytokines
involved in this process are well known and have been the
object of several studies [12,13], pointing out that TNFα,
and IL-7 are involved in OCs differentiation [13]. Osteo-
clasts thus represent a link between joint inflammation
and structural damage [6]. Hence, therapeutic approaches
inhibiting osteoclastogenesis have been proposed by sev-
eral authors for rheumatoid arthritis therapy [14-20].
These drugs are also expected to be of interest in the ther-
apy of other pathologies associated with bone loss, such
as osteoporosis [21-23] and bone metastasis [24-27], as
inhibition of bone resorption, aimed at preventing further
bone loss, is based on the efficient targeting of OCs func-
tion [21-27]. In conclusion, several therapeutic
approaches are based on inhibition of osteoclast-depend-
ent bone resorption through inhibition of OCs differenti-
ation or stimulation of OCs apoptosis.
Recent results support the concept that some medicinal
plants and natural products derived from them are of
great interest for developing therapeutic strategies against
bone disorders, including rheumatoid arthritis and oste-
oporosis [28-33]. Yin J. et al. demonstrated that water
extracts of Dioscorea spongiosa stimulate osteoblasts prolif-
eration, exhibiting at the same time a potent inhibitory
activity on osteoclastogenesis [34]. Fruit extracts of Psor-
alea corylifolia [35] and Cnidium monnieri [36] have been
shown to exhibit osteoblastic proliferation stimulating
activity in osteoblast-like UMR106 cells in vitro. Several
plant extracts inhibiting OCs differentiation also display
strong anti-inflammatory properties [34-36].
Emblica officinalis is certainly a medicinal plant of interest
[37-45]. It has played an important medicinal role for cen-
turies in the Indian system of medicine. Fruits of E. offici-
nalis are used for the treatment of a number of diseases,
such as dyslipidemia [37] and atherosclerosis [38], as
hepatoprotective [39], antibacterial [40] and anti-inflam-
matory agent [41]. In many cases, E. officinalis has been
shown to be a potent free radical scavenging agent thereby
preventing carcinogenesis and mutagenesis [42].
In this study we investigated whether extracts of Emblica
officinalis fruits display effects of possible interest for the
treatment of rheumatoid arthritis and osteoporosis, by
activating programmed cell death of human primary oste-
oclasts. The effects of E. officinalis on human osteoclasts
obtained from peripheral blood mononuclear cells
[46,47] were analyzed by determining the proportion of
apoptotic OCs. The effects of Emblica officinalis extracts
were studied also on NF-kB/DNA interactions by electro-
phoretic mobility shift assay [48], given the possible
involvement of the NF-kB transcription factor on the
maintenance of the differentiation program of osteoclasts
[49-51]. The effects of Emblica officinalis extracts on the
expression of NF-kB dependent genes were also deter-
mined.
Methods
Culture of human primary osteoclasts
Human OCs were prepared as reported by Mitsuzaki et al.
[52] with slight modifications. Peripheral blood was col-
lected from healthy normal volunteers after informed
consent. Mononuclear cells (PBMCs) were prepared from
diluted peripheral blood (1:2 in Hanks Balanced Salt
Solution), which was layered over Histopaque 1077
(Sigma, St. Louis, MO, USA) solution, centrifuged (400
g), washed and suspended in D-MEM/10% FCS. 3 × 106
PBMCs/cm2 were plated in 24-well plates or in chamber
slides and allowed to settled for 2 hours. Wells were then
rinsed to remove non-adherent cells. Monocytes were
maintained at 37°C, in 5% CO2, in medium supple-
mented with 10% FCS and cultured for 14 days in the
presence of human M-CSF (25 ng/ml), RANKL (30 ng/ml)
and 10-7 M PHT. Culture media were replenished with
fresh media every 3–4 days. Cells were used for the
described experiments when mature multinuclear cells
were predominant in the cultures.
Tartrate-resistant acid phosphatase (TRAP) staining
TRAP staining of the cells was performed as reported by
Villanova et al. [53]. Cells were fixed in 3% para-formal-
dehyde with 0.1 M cacodilic buffer, pH 7.2 (0.1 M
Sodium cacodilate, 0.0025% CaCl2) for 15 min, exten-
sively washed in the same buffer, and stained for TRAP
(Acid Phosphatase Kit n. 386 – Sigma, St. Louis, MO,
USA). After washing with distilled water and drying,
mature TRAP positive multinucleated cells containing
more than three nuclei were considered as osteoclasts.Page 2 of 11
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The dried fruits of Emblica officinalis were extracted with
absolute ethanol and the yield was 9.33%. The chemical
composition has been determined by GC/MS and was
reported elsewhere [54,55].
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assay (EMSA) was per-
formed by using double stranded 32P-labelled oligonucle-
otides as target DNA [51]. Binding reactions were set up as
described elsewhere in binding buffer (10% glycerol,
0.05% NP-40, 10 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.5
mM DTT, 10 mM MgCl2), in the presence of
poly(dI:dC).poly(dI:dC) (Pharmacia, Uppsala, Sweden),
2 μg of crude nuclear extracts and 0.25 ng of labelled oli-
gonucleotide, in a total volume of 20 μl [28]. After 30 min
binding at room temperature, samples were electro-
phoresed at constant voltage (200 V for 1 hr) through a
low ionic strength (0.25 × TBE buffer) (1 × TBE = 0.089 M
Tris-borate, 0.002 M EDTA) on 6% polyacrylamide gels
until the tracking dye (bromophenol blue) reached the
end of a 16 cm slab. Gels were dried and exposed for auto-
radiography with intensifying screens at -80°C. In these
experiments, DNA/protein complexes migrate through
the gel with slower efficiency. In studies on the inhibitors
of protein/DNA interactions, the addition of the reagents
was as follows: (a) poly(dI:dC).poly(dI:dC); (b) labelled
oligonucleotides mimicking the binding sites for tran-
scription factors to be analyzed; (c) plant extracts; (d)
binding buffer; (e) nuclear factors. The nucleotide
sequences of double-stranded target DNA utilized in these
experiments were 5'-CGC TGG GGA CTT TCC ACG G-3'
(sense strand, HIV-NF-kB binding site), and 5'-CTG ATT
TCC CCG AAA TGA CGG-3' (sense strand, STAT-3 bind-
ing site).
Measurement of apoptosis
After 14 days of cell culture and 2–3 days of incubations
with E. officinalis extracts, the cells were rinsed twice with
PBS solution and fixed for 25 min in 4% paraformalde-
hyde at room temperature. Apoptotic cells were detected
by the DeadEnd Colorimetric Apoptosis Detection System
(Promega) according to the manufacturer's instructions.
Measurement of apoptosis was calculated as a percentage
of apoptotic nuclei (dark brown nuclei) versus total nuclei
of multinucleated TRAP positive cells, evaluated in three
independent measurements. A dark brown DAB signal
indicates positive staining, while shades of blue-green to
greenish tan indicate a nonreactive cell [46,47].
Immunocytochemistry analysis
Immunocytochemistry analysis was performed employ-
ing the streptavidin-biotin method using Ultraystain Poly-
valent-HRP Immunostaining Kit. OCs grown in
multichamber slides were fixed in 100% cold methanol,
and permeabilized with (v/v) Triton X-100 (Sigma) in TBS
(Tris-buffered saline). Cells were incubated in 3% H2O2
and blocked with Super Block reagent (Ultraystain Poly-
valent-HRP Immunostaining Kit). After the reaction with
the primary antibodies, rabbit polyclonal antibodies of
human origin (Santa Cruz Biotech) against MMP9, FAS
receptor, IL-6, and NF-kB (2 mg/ml) were used accord-
ingly to the manufacturer's protocols, at 1:500 (MMP9),
1:100 (FAS receptor), 1:800 (IL-6) and 1:800 (NF-kB)
dilutions. Incubation was carried out at 4°C for 16 hr.
Cells were then incubated at room temperature with anti-
polyvalent Biotinylated Antibody (Ultraystain Polyvalent-
HRP Immunostaining Kit). After rinsing in TBS, Streptavi-
din HRP (Ultraystain Polyvalent-HRP Immunostaining
Kit) was applied, followed by the addition of Substrate-
chromogen mix (AEC Cromogeno kit). After washing,
cells were mounted in glycerol/TBS 9:1 and observed
using a Leitz microscope [46,47].
Cytotoxicity studies
The cytoxicity analysis was determined on in vitro cultured
human OCs. PBMCs were plated in 96-well plates and,
after 14 days, OCs were incubated with E. officinalis plant
extracts for 3 days. Determinations of viable cells were
performed after colorimetric assay with MTT (thiazolyl
blue). The assay, based on the conversion of the yellow
tetrazolium salt MTT to purple formazan crystals by met-
abolically active cells [56], provides a quantitative deter-
mination of viable cells. After 72 hr of treatments in
triplicate, 200 μL of MTT was added to each well of cells,
and the plate was incubated for 2 hr at 37°. The medium
was removed, and the MTT crystals were solubilized with
50% DMF. Spectrophotometric absorbance of each sam-
ple was then measured at 570 nm.
Statistical analysis
Data are presented as the mean ± SEM from at least three
independent experiments. Statistical analysis was per-
formed by one-way analysis of variance followed by the
Student's t-test. A P value < 0.005 was considered statisti-
cally significant.
Results
Effects of Emblica officinalis extracts on differentiation 
and viability of human primary osteoclasts
Human primary osteoclasts were obtained from periph-
eral blood and cultured in complete D-MEM plus MCSF,
PTH and RANKL for 14 days. OCs differentiation was
tested by tartrate-acid resistant acid phosphatase (TRAP)-
positivity (Fig. 1) and metalloproteinase-9 (MMP-9)
expression (data not shown). In order to test the effect of
E. officinalis extracts on osteoclast differentiation, mature
OCs (Fig. 1A) or monocytes during the two weeks of
induction (Fig. 1B) were exposed to 0.5, 5, 50 μg/ml of
plant extracts. The conditions used for these experimentsPage 3 of 11
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TRAP staining analysis of human primary osteoclasts obtained after 14 days of culture in presence of 0.5, 5, and 50 μg/ml of Emblica officinalis extracts, as indicated (A); the same percentage of multinucleated TRAP-po itive cells was obtained when mature steoc asts were grown fo  60 hours with he same amount of Emblica officinalis extracts (B). Cells were photographed at the 20 × m g ificationFig 1
TRAP staining analysis of human primary osteoclasts obtained after 14 days of culture in presence of 0.5, 5, 
and 50 μg/ml of Emblica officinalis extracts, as indicated (A); the same percentage of multinucleated TRAP-pos-
itive cells was obtained when mature osteoclasts were grown for 60 hours with the same amount of Emblica 
officinalis extracts (B). Cells were photographed at the 20 × magnification. In the lower part of the panel data from five 
determinations are presented (average ± SD).
BMC Complementary and Alternative Medicine 2008, 8:59 http://www.biomedcentral.com/1472-6882/8/59correspond to the concentrations of E. officinalis extracts
leading to 50% of inhibition (IC50 value) of cell growth,
previously analyzed in different cell lines [55]. As reported
in Figure 1, the presence of comparable levels of TRAP-
positive cells cultured both in presence and in absence of
E. officinalis extracts did not affect the process of osteoclas-
togenesis, at the concentrations employed. Quantitative
data from three independent experiments are presented in
the lower sides of Figure 1, demonstrating that treatment
of the cultures with E. officinalis extracts does not have
inhibitory effects on the development of TRAP-positive
OCs. Cytotoxic effects of E. officinalis extracts were then
analyzed. Human primary OCs were treated with increas-
ing amount of E. officinalis extracts (0.5–500 μg/ml) for 72
hours and the viability of the cells was examined by the
colorimetric MTT assay [56]. As shown in Figure 2, 0.5, 5
and 50 μg/ml of E. officinalis extracts did not cause any
cytotoxic effect on the total cell population (1–5% of
which is constituted by OCs). Only E. officinalis extracts
used at 500 μg/ml were found to induce a slight but not
significant decrease of viability.
Emblica officinalis extracts induce apoptosis of 
osteoclasts
In a previous study we demonstrated that in different cell
lines (K562, B-lymphoid Raji, T-lymphoid Jurkat and HEL
cells) E. officinalis extracts retain an antiproliferative effect
[55]. In the present paper we investigated osteoclasts in
terms of apoptosis. To this aim, TUNEL test was per-
formed on OCs after exposure, up to 60 hours, to 0.5, 5,
and 50 μg/ml of E. officinalis extracts. As shown in the rep-
resentative experiment reported in Figure 3 (panels A and
B), a low but significant level of apoptosis (20%) was
induced by 0.5 μg/ml of extract; at 5 and 50 μg/ml, a dra-
matic increase (respectively 50% and 98%) in TUNEL-
positive nuclei was observed. Table 1 reports summary
data from three independent experiments, confirming the
observation that 5 and 50 μg/ml of E. officinalis extracts
consistently induce high levels of apoptosis of osteoclasts.
Times of exposure shorter than 60 hours were also tested
(24 and 48 hours) without obtaining significant differ-
ences from untreated cells (data not shown). These results
were confirmed by immunocytochemical analysis of FAS
receptor, a well known apoptosis-related protein [57],
whose expression increased, as shown in Figure 3C, in
OCs treated with E. officinalis extracts at all the concentra-
tions used. When extracts from different medicinal plants,
such as Satureja montana and Satureia hortensis were
employed, no OCs apoptosis was induced (data not
shown).
Effect of different concentrations (0.5–500 μg/ml) of Emblica officinalis extract on cell survival of human primary osteoclast obtained by MTT lorimetr c a sayFigur  2
Effect of different concentrations (0.5–500 μg/ml) of Emblica officinalis extract on cell survival of human pri-
mary osteoclast obtained by MTT colorimetric assay. Results are expressed as the percentage of surviving cells and are 
the average ± SD of three independent experiments. The viability of controls only treated with vehicle (H2O) has been set as 
100%.Page 5 of 11
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transcription factor activity
The ability of E. officinalis extracts to interfere with NF-kB
binding to DNA was investigated, given that the transcrip-
tion factor NF-kB plays a critical role in OCs activities by
regulating the expression of a large number of OCs spe-
cific genes [48-50]. E. officinalis extracts were incubated in
presence of 5 μg of nuclear extracts from K562 cells with
an oligonucleotide containing a cis element of the LTR of
HIV-1 representing the DNA binding site for NF-kB. DNA-
protein interactions were then analyzed by EMSA [51]. As
reported in Figure 4, a dose dependent effect was
observed, indicating the ability of E. officinalis extracts to
completely inhibit NF-kB interaction with its cis element,
when used at 100, 50, and 25 μg/reaction. On the con-
trary, 100 μg of E. officinalis extracts were not able to abol-
ish the DNA-protein interactions of the transcription
factor STAT-3 with its cis element (right side of Fig. 4)
indicating a selectivity of the effects of E. officinalis extracts
for NF-kB/DNA interactions. The sensitivity of NF-kB/
DNA interactions to E. officinalis extracts was demon-
strated to be related to the type of plant extracts and not
A, B. Detection of apoptosis by TUNEL assay in human primary osteoclastsFigure 3
A, B. Detection of apoptosis by TUNEL assay in human primary osteoclasts. The presence of apoptotic OCs after 
treatment with 0.5, 5, 50 μg/ml of Emblica officinalis extract for 60 hours is shown in panel A. Brown color reaction indicates 
cells that underwent apoptosis. Quantitative results of the experiment shown in panel A are depicted in panel B (the data 
reported represent the average ± SD of six independent determinations). C. Immunocytochemical analysis of FAS receptor 
expression levels in human primary osteoclasts subjected to the same experimental conditions reported in panel A. (-): control 
cells. Cells were photographed at the 20 × magnification.Page 6 of 11
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observed (a) with the extracting buffer and (b) other
extracts from medicinal plants, such as Oroxylum indicum,
Cuscuta reflexa, Paederia foetida, Hygrophilla auriculata, Oci-
mum sanctum (data not shown and Lampronti et al.) [57].
In order to determine whether E. officinalis extracts affect
NF-kB dependent biological activity in OCs, we have eval-
uated the effects of the plant extracts on the expression of
IL-6, a target gene of NF-kB transcription factors [58,59].
Immunocytochemical analysis, reported in Figure 5,
clearly shows a significant decrease of IL-6 levels in OCs
treated with 5–50 μg/ml of E. officinalis extracts after com-
parison to control untreated cells.
Discussion
The present study suggests the employment of primary
cultures of human osteoclasts as a tool to test the potential
interest of extracts of Emblica officinalis fruits in the exper-
imental therapy of human pathologies associated with
bone loss, including osteoarthritis and osteoporosis. The
possible use of natural products, including plant extracts
and nutriaceuticals, is under debate. A systematic review
of the scientific evidence supporting the hypothesis that
nutrition can improve the symptoms of declared osteoar-
thritis has been recently published [60]. In addition, the
possible use of medicinal plant extracts or single products
derived from them for preventing or treating experimen-
tally rheumatoid arthritis has been reported [31-33]. In
this respect, one of the best example is Turmeric, derived
from the plant Curcuma longa, a gold-colored spice com-
monly used in the Indian subcontinent in Ayurvedic med-
icine as a treatment for inflammatory disorders, including
Table 1: Apoptotic osteoclasts following treatment with E. 
officinalis extracts
Experiment E. officinalis extracts (μg/ml)
0 0.5 5 50
A 2 20 33 97
B 3 15 58 98
C 2.5 55 65 99
Detection of apoptosis of human primary OCs was performed by 
TUNEL assay. Treatment with 0.5, 5, 50 μg/ml of Emblica officinalis 
extracts was carried on for 60 hours. See Figure 3 for additional 
information.
Analysis by electrophoretic mobility shift assay of the effects of Emblica officinalis extracts on NF-kB DNA binding activityFigure 4
Analysis by electrophoretic mobility shift assay of the effects of Emblica officinalis extracts on NF-kB DNA 
binding activity. Nuclear extracts from the K562 cell line were incubated with 32P-labelled oligonucleotides (*) NF-kB and 
STAT-3, in the presence of different amounts (100, 50, 25, 12.5, 6, 3, 1.5, 1 μg) of Emblica officinalis extracts. Protein/DNA 
complexes and free probe are indicated by arrows.Page 7 of 11
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supplements containing turmeric rhizome and curcumin-
oid-containing turmeric extracts are used in the western
world for arthritis treatment and prevention [31].
Emblica officinalis is reported to have antitumor activity
[42,45,54] together with beneficial effects in gynecologi-
cal, hepatic, respiratory and skin [43,44] disorders. How-
ever, the biological activity of Emblica officinalis extracts of
possible interest for treatment of arthritis and osteoporo-
sis have not yet been reported. To verify this effect in vitro
different experimental approaches should be used in par-
allel, including analysis of possible positive effects on
osteoblastogenesis and negative effects on osteoclastogen-
esis. In fact, increase of bone formation, leading to anti-
osteoporotic and anti-osteoarthritis activity, could be
obtained by induction of osteoblast activity, inhibition of
osteoclast bone resorption, or both of these effects. In pre-
vious studies [34-36] osteoblast-like UMR106 cells,
derived from a rat osteogenic sarcoma, were used to screen
drugs and plant extracts for stimulation of bone forma-
tion.
The aim of our study was to determine the activity of E.
officinalis extracts on osteoclasts, using primary OCs of
human origin isolated from peripheral blood and incu-
bated for different length of time and with different
amounts of E. officinalis extracts. The analysis of cellular
Different expression of IL-6 in human primary osteoclasts analyzed by immunocytochemistry with specific antibody after incu-bation for 60 hours in the absence (-), or in the presence of 0.5, 5 and 50 μg/ml of Emblica officinali  extractsFigu  5
Different expression of IL-6 in human primary osteoclasts analyzed by immunocytochemistry with specific 
antibody after incubation for 60 hours in the absence (-), or in the presence of 0.5, 5 and 50 μg/ml of Emblica 
officinalis extracts. Cells were photographed at the 20 × magnification.Page 8 of 11
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extracts do not have any cytotoxic effect, even at a concen-
tration of 500 μg/ml, still inducing significant level of
apoptosis. This effect was confirmed by the finding of
increasing levels of FAS receptor after treatment with both
high and low concentrations of E. officinalis extracts.
Hence, we conclude that E. officinalis extracts are strong
inducers of the apoptotic pathway of primary human
osteoclasts.
Since the transcription factor NF-kB has been reported to
be important for the expression of several osteoclast-spe-
cific genes, we verified whether E. officinalis extracts were
able to inhibit the biological activity of this factor. An
electrophoretic mobility shift assay demonstrated that
NF-kB/DNA complexes are inhibited after incubation of
nuclear DNA-binding proteins with increasing amounts
of E. officinalis extracts. Accordingly, when the analysis
was carried on cultured OCs, high levels of inhibition of
IL-6, a NF-kB modulated protein were found, further dem-
onstrating that NF-kB dependent biological functions are
impaired following treatment with E. officinalis extracts.
On the basis of this experimental evidence we propose
that the pro-apoptotic action of E. officinalis extracts on
osteoclasts could be mediated, at least in part, by interfer-
ing with NF-kB activity.
Interestingly, the effects on human OCs of E. officinalis
extracts are similar to those reported for other inhibitors
of NF-kB functions, such as biphenylcarboxylic acid
butanediol ester (ABD56) [61] and genistein [62]. In
addition the effects of E. officinalis extracts are almost over
imposable to those of a decoy double-stranded oligonu-
cleotide mimicking NF-kB binding sites [46]. Similarly to
this decoy oligonucleotide, E. officinalis extracts, at the
concentrations employed, induce OCs apoptosis without
inhibiting osteoclastogenesis. An effect of E. officinalis at
higher concentrations cannot be excluded; however, at
these levels a certain cytotoxicity (see Figure 2) renders
difficult the discrimination between a possible inhibitory
effect on OCs differentiation and an overall antiprolifera-
tive activity.
Finally, we like to point out that our results are based on
an in vitro approach, and specificity in vivo of the effects
here described should be carefully determined, since the
transcription factor NF-kB is also important for other cel-
lular systems, including macrophages, that when exposed
to the extracts may overwhelm the effects on osteoclasts.
In this respect, several in vivo systems suitable for testing
inducers of OCs apoptosis are now available [63-65].
Conclusion
The data here reported on the effects of E. officinalis
extracts on mature human osteoclasts suggest the possible
use of this medicinal plant as a therapeutic tools against
different forms of arthritis and osteoporosis, improving
the activity of already employed drugs. In addition, E.
officinalis extracts could be analyzed to identify single
compounds responsible for the biological activity identi-
fied.
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